Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    Home»HealthCare»EC Healthcare Announced Quarterly Sales Volume, Successfully Expanded New Flagship Service Centre
    HealthCare

    EC Healthcare Announced Quarterly Sales Volume, Successfully Expanded New Flagship Service Centre

    Marie JonesBy Marie JonesJuly 27, 2021No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    EC Healthcare (the Company, which together with its subsidiaries is referred to as the Group, HKG: 2138), the largest non-hospital medical group in Hong Kong, announces that to fulfill the strong demand for medical and healthcare services, on 26 July 2021, the Group has expanded its flagship service centre at Langham Place Office Tower in Mong Kok, with a newly leased floor with a gross floor area of approximately 17,900 square feet. The newly leased floor is for the Group’s businesses of aesthetic medicine and medical specialist services, including but not limited to the Group’s first ophthalmology centre and a new obstetrics and gynecology centre.

    After the expansion, the total service area of the Group in Langham Place Office Tower has increased to 9 floors and the aggregate floor area of the clinics and service centres of the Group increased to approximately 431,000 square feet.

    The Board believes the aforementioned expansion will become a growth driver for the Group’s businesses, further consolidate the Group’s position in the industry as a one-stop comprehensive healthcare and medical service provider, and effectively expand its healthcare and medical market share.

    For April to June 2021, the Group expects to record:

    (i) overall Sales Volume of no less than HK$720 million for the Quarter, representing an increase of no less than 52% as compared with the same period last year and an increase of no less than 35% as compared with the same period in 2019;

    (ii) an increase in Sales Volume in those clinics and service centers located in Mainland China of no less than 36% for the Quarter as compared with the same period last year and an increase of no less than 91% as compared with the same period in 2019; and

    (iii) an increase in Sales Volume of medical services offered by the Group of no less than 104% for the Quarter as compared with the same period last year and an increase of no less than 131% as compared with the same period in 2019.

    About EC Healthcare

    EC Healthcare is Hong Kong’s largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group’s high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.

    The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories and a professional hair care center HAIR FOREST.

    *According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleSingapore cord blood bank Cryoviva establishes footprint in the UAE
    Next Article Motul powers Honda motorbikes to a weekend full of victories

    Related Posts

    CanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth

    October 27, 2026

    Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

    October 27, 2026

    Micot Pharma Showcases First-in-Class, Brain-Penetrant TrkB Agonist MT200605 at World Stroke Congress, Building the Case for Global Partnerships and Commercialization

    October 27, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • Garuda Indonesia Advances Digital Transformation, Expands Travel Flexibility with Upgraded Manage My Booking Service
    • Chervon Launches Advanced Momentum Program (AMP) to Hire & Develop the Next Generation of Leaders
    • Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers
    • OMRON Healthcare Begins Full-Scale Production at First Factory in India
    • Rasa Light Je: Spritzer Sparkling Invites Malaysians to Go Light on Themselves with a Positive Approach to Everyday Wellbeing
    • Garuda Indonesia Group’s Transformation Programme Drives 13.2% Revenue Growth to US$2.71 Billion Amid High Jet Fuel Prices
    • CIMC Group Announces Results for the First Three Quarters of 2026
    • TANAKA MIRAI Lab., JAF MEDIA WORKS, and Della Begin Joint Research to Visualize Drivers’ Conditions through Analysis of Sweat Components
    • U.S. Polo Assn. Executes Early on Europe’s Digital Product Passport Mandate
    • COSCO SHIPPING Ports Announces 2026 Third Quarter Results
    © 2026 BusinessNewsAsia.com

    Type above and press Enter to search. Press Esc to cancel.